Sanofi Shares Bounce Back at Close Following Dynavax Acquisition Announcement
Sanofi's stock ended the session on Monday, December 29, with a gain of 0.77%, at 82.24 euros, amid a strategic acquisition announced the previous week. The stock is trading below its moving averages, but an indicator shows potential for a technical rebound.
Impact of Dynavax Acquisition on Sanofi's Financial Outlook
The acquisition of Dynavax for $2.2 billion, announced on December 24, will not impact Sanofi's 2025 financial forecasts. The stock closed Monday at 82.24 euros, up 0.77% from the previous day, in reduced volumes representing 0.05% of the traded capital. This operation strengthens the French laboratory's presence in adult immunization with the integration of the HEPLISAV-B hepatitis B vaccine and a shingles vaccine candidate in clinical phase. However, the stock remains under structural pressure, showing a decline of 11.58% over the year, despite a positive quarterly performance of 5.31%. The stock is trading below its main moving averages, at 83.48 euros for the MM20 and 85.71 euros for the MM50, confirming a medium-term downward trend. The RSI is at 36, indicating that the stock is approaching an oversold zone without yet entering it, which could signal a possible technical rebound. The support threshold at 80.60 euros remains a key level to watch in case of continued weakness.
Sanofi's Search for New Growth Drivers
Sanofi is seeking new growth drivers before the patent expiration of Dupixent in 2031, having already completed the acquisition of Vicebio for $1.5 billion in July and of Blueprint Medicines. This strategy is part of an environment marked by recent clinical disappointments. The FDA has refused approval of tolebrutinib for multiple sclerosis, adding to a year of disappointing data on experimental treatments for eczema and pulmonary diseases. Regarding recommendations, analysts remain generally positive despite setbacks. Berenberg maintains a buy rating with a target price of 105 euros, representing a potential upside of 27% from the current price. HSBC and Jefferies also have targets of 98 euros, while Deutsche Bank aims for 110 euros. However, the price is still significantly below the upper Bollinger band at 87.09 euros, indicating that volatility remains contained and the stock struggles to regain bullish momentum in the short term.
